Drug intelligence / Profile preview

succimer

Development stage
Approved
Lead developer
Bock Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Succimer (meso-2,3-dimercaptosuccinic acid) is an orally active heavy metal chelating agent. It contains two sulfhydryl (thiol) groups that form stable, water-soluble complexes with metal cations, facilitating their renal excretion. Succimer is significantly less toxic than the parenteral chelator dimercaprol (BAL) and is the first orally effective treatment for lead poisoning. Its primary FDA-approved indication is for the treatment of lead poisoning in pediatric patients with blood lead levels exceeding 45 µg/dL. Beyond lead, succimer is utilized off-label or in specific international markets for the treatment of mercury and arsenic poisoning, as well as Wilson's disease (hepatolenticular degeneration) due to its ability to chelate copper.

Brand names
Chemet
Other names
meso-2,3-dimercaptosuccinic acidDMSAdimercaptosuccinic acidmeso-DMSA

Beyond the preview

Go deeper on succimer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on succimer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call